Bufuralol, Dextromethorphan, and Debrisoquine As Prototype Substrates for Human P450IID6
Overview
Authors
Affiliations
Davydov D, Davydova N, Rodgers J, Rushmore T, Jones J Biochem J. 2017; 474(20):3523-3542.
PMID: 28904078 PMC: 5798876. DOI: 10.1042/BCJ20170543.
Okabe H, Hasunuma M, Hashimoto Y Pharm Res. 2003; 20(10):1591-4.
PMID: 14620512 DOI: 10.1023/a:1026131216669.
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger U, Raimundo S, Eichelbaum M Naunyn Schmiedebergs Arch Pharmacol. 2003; 369(1):23-37.
PMID: 14618296 DOI: 10.1007/s00210-003-0832-2.
Prakash C, Kamel A, Cui D, Whalen R, Miceli J, Tweedie D Br J Clin Pharmacol. 2000; 49 Suppl 1:35S-42S.
PMID: 10771452 PMC: 2015052. DOI: 10.1046/j.1365-2125.2000.00151.x.
Synthetic strategies to lower affinity for CYP2D6.
Halliday R, Jones B, Park B, Smith D Eur J Drug Metab Pharmacokinet. 1998; 22(4):291-4.
PMID: 9512923 DOI: 10.1007/BF03190959.